The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

Amid growing pressure on the U.S. healthcare system to meet the needs of its aging population, the Digital Medicine Society (DiMe) launched a new initiative this month to build a roadmap for ...

An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The ...